Lymphoma Treatment Flashcards
ABVD
treatment for Hodgkin Lymphoma
highly emetogenic
Adriamycin (doxorubicin)
Bleomycin
Vinblastine
Dacarbazine
Doxorubicin
Hodgkin Lymphoma
AEs:
- hepatic impairment (adjust)
- Myelosuppression
- Vesicant
- cardiotoxicity
evaluate LVEF at baseline and d/c if < 30%
keep track of cumulative dose
Bleomycin
Hodgkin Lymphoma
AEs:
- BBW: pulmonary fibrosis
- anaphylactoid-type reaction (with first and second dose, observe for ONE HOUR)
- renal adjust
monitor for respiratory complaints
keep track of cumulative dose
Vinblastine
Hodgkin Lymphoma
AEs:
- vesicant
- hepatic dysfunction (adjust)
- leukopenia (DLT)
- constipation and paralytic ileus
must be on bowel regimen
CANNOT give intrathecally
DDIs: CYP3A4 and p-gp substrate
Dacarbazine
Hodgkin Lymphoma
AEs:
- BW: hepatotox
- irritant/vesicant (use central line)
- renal dysfunction (adjust)
- myelosuppression (monitor CBC)
highly emetogenic
Brentuximab vedotin
antibody-drug conjugate: CD30 = target
Hodgkin Lymphoma
AEs:
- Progressive Multifocal Leukoencephalopathy
- peripheral neuropathy
- hepatotox (adjust as well)
- pancytopenia
- pulmonary tox (do NOT use with bleo)
- avoid if CrCl < 30
DDIs:
CYP3A4 substrate
R-CHOP
first line for diffuse large B-cell lymphoma (non-hodgkin)
Rituximab Cyclophosphamide Hydroxydaunorubicin (doxorubicin) Oncovin (Vincristine) Prednisone
CAR-T therapy
for refractory DLBCL (non-hodgkins)
Rituximab
Non-Hodgkins
AEs:
- BBW: SJS
- BBW: Tumor Lysis Syndrome
- infusion reaction w/in 30 - 120 minutes
- Reactivation of Hep B
Admin:
- premed with acetaminophen and antihistamines
Monitoring:
stop or slow infusion if infusion reaction occurs, give bronchodilators, epi, corticosteroids
Vincristine
Non-Hodgkins
AEs:
- peripheral neuropathy and neurotox (DLT
- constipation and paralytic ileus
- vesicant
Fatal if given intrathecally
baseline neuro exam and clinical history
bowel regimen required
DDIs: CYP3A4 substrate, p-gp substrate
